hollandbio

A circular economy is indispensable for a future world. By using materials smarter, reducing waste and making the most of raw materials, we are building a society that is not only climate-friendly, but also economically strong and competitive. The urgency to make this transition is widely recognised, but the role of biotech in accelerating it remains underscored.

Filed in Dutch · English published by the European Commission

Hollandbio welcomes the European Commissions Industrial Decarbonisation Accelerator Act (IDA Act). For the Act to succeed, it must recognise biotechnology as one of the key drivers of the transition to climate neutrality. Biotech delivers practical, scalable solutions across sectors from chemicals and materials to food, waste, and carbon use.

IVDR/MDR revision: cautiously clarify a viable route from lab to practice When you are ill, you just want one thing: improve. Prefer to stay healthy. At a time when bespoke health is emerging thanks to advances in diagnostics, disease models and treatment options, hollandbio sees innovative diagnostics that help make bespoke work possible in practice as stumbling away from a forest of rules and procedures, including…

Filed in Dutch · English published by the European Commission

Diagnostics as a key to bespoke health When you are ill, you want only one thing: improve. Prefer to stay healthy. The right treatment at the right time for the right patient is getting closer, thanks to advances in diagnostics and treatments. Only these innovations need to achieve this in practice. At a time when the technology is ready to deliver bespoke health, it is stuck in a forest of rules and procedures.

Filed in Dutch · English published by the European Commission

1 Consultation input — The Hague, 11 August 2025 Transform the EU from company nursery to powerhouse Europe is known as a forward-thinking continent, where knowledge and innovation have been at its core for centuries. What was true then remains relevant today. Yet, we are at risk of being overtaken by countries like the United States and China. That’s unfortunate - and not without consequences.

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

Hollandbio’s response to the main lines of the review of the EU’s general pharmaceutical legislation can be found on our website: https://www.hollandbio.nl/nieuws/grijp-die-kans-geneesmiddelen-sneller-beter-slimmer-goedkoper-en-groener-beschikbaar-dankzij-herziening-eu-geneesmiddelenwetgeving/ in addition to this, in the excel attached, we set out our more detailed position with regard to the different measures.

Filed in Dutch · English published by the European Commission

HollandBIO, the Dutch biotech industry association, appreciates the opportunity to provide feedback on the roadmap towards the evaluation and revision of the general pharmaceutical legislation to further improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. An ambition very close to our heart.

Hollandbio, the Dutch biotech association, welcomes the ambition to strengthen biotech as one of Europes key technologies for health, sustainability, resilience and economic prosperity. More than ever, global challenges and geopolitics underline biotechs strategic importance.

Europe worked hard to become a leader in biotech. But while the rest of the world is taking the next step, we are blocking ourselves. Innovations get stuck in outdated rules and fragmented regulations, talent moves elsewhere, and other continents capitalize on European breakthroughs.

Biotechnology and biomanufacturing are critical for Europes future competitiveness, sustainability and strategic autonomy. While the EU has a strong scientific base and broad political support for biotechnology, its potential remains underutilised due to persistent structural barriers that limit scale-up, market entry and uptake.

At hollandbio, the Dutch biotech association, we are convinced that biotech makes life better. To capitalize on the opportunities of the global biorevolution for health, sustainability, and the economy, a paradigm shift is needed. Instead of amending the current outdated laws and regulations for genetic modification, hollandbio prefers a fresh start with a clean slate.

Hollandbio is the Dutch industry association for biotechnology companies, representing start-ups, scale-ups, established companies and multinational enterprises. Our members include plant breeders and other companies that develop and apply new genomic techniques. Drawing on their scientific expertise and practical experience, we welcome the opportunity to provide input implementing act for Category 2 NGT plants.

Hollandbio is the Dutch industry association for biotechnology companies, representing start-ups, scale-ups, established companies and multinational enterprises. Our members include plant breeders and other companies that develop and apply new genomic techniques.

HollandBIO, the Dutch biotech industry association, appreciates the opportunity to provide feedback on the inception impact assessment on the revision of the EU legislation on medicines for children and rare diseases. We endorse the four objectives for the revision of the two Regulations. We acknowledge there is room to improve and strengthen the effectiveness of the legislation.

Europe has always been a continent of pioneersturning challenges into opportunities and building a future on knowledge, courage, and collaboration. Our leadership in innovation is no coincidence; its the result of decades of smart investment and bold choices.